Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a major public health problem, requiring the use of last-resort antibiotics such as colistin. However, there is concern regarding the emergence of isolates resistant to this agent. The report describes two patients with urinary tract infection (UTI) and ventilator-associated pneumonia (VAP) infection caused by CRKP strains. The first case was a 23-year-old male with UTI caused by a strain of ST16 co-harboring blaCTX-M, blaTEM, blaSHV, blaNDM, blaOXA-48-like genes. The second case was a 39-year-old woman with VAP due to hypervirulent ST337-K2 co-harboring blaSHV, blaNDM, blaOXA-48-like, iucA, rmpA2 and rmpA. The patients’ general condition improved after combination therapy with colistin (plus meropenem and rifampin, respectively) and both of them recovered and were discharged from the hospital. This study highlights the necessary prevention and control steps to prevent the further spread of CRKP strains should be a priority in our hospital.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Carbapenem-Resistance Klebsiella pneumoniae (CRKP) is a major global public health threat that can cause invasive hospital-acquired infections among patients and is therefore associated with high morbidity and mortality [1]. The rise of this pathogen has led to the resurgence of colistin as a last-resort therapy. Classic K. pneumoniae (cKPs) and hypervirulent K. pneumoniae (hvKPs) are two different variants of K. pneumoniae. hvKp is an evolving pathotype that is considered to be more virulent than classical cKp in both basic research and clinical research [2]. In recent years several studies have reported the existence and increasing prevalence of multidrug-resistant hvKP strains, especially extended-spectrum β-lactamase (ESBL)-producing hvKP and carbapenem-resistant hvKP [3, 4]. In Iran, due to the increase in the prevalence of carbapenemase-producing K. pneumoniae isolates, colistin consumption has increased significantly, which has already caused the emergence of colistin-resistant isolates [4, 5]. Here, we present the clinical and microbiological findings of two patients who developed infection caused by ST337-K2 carbapenemase-producing-hvKp and ST16 carbapenemase-producing infection. Both patients were treated successfully with colistin combination therapy and discharged from the hospital.
Case presentation
Case 1
On October 6, 2020, a previously healthy 23-year-old male patient was admitted to the emergency department following a fall from a height, resulting in multiple traumas. His initial vital signs were as follows: blood pressure of 131/82 mmHg, pulse of 90 bpm, respiratory rate 20 of breaths/min, and body temperature of 37 ℃. The patient, with no prior medical history, underwent intubation and was subsequently admitted to the intensive care unit (ICU) with a diagnosis of subdural hematoma and pleural effusion. After being admitted, he was empirically treated with intravenous ceftazidime (1 g IV every 8 h, 11 days) and clindamycin (600 mg IV every 8 h, 11 days). On the 5th day of admission, vancomycin was experimentally added to the antibiotic treatment by the infectious specialist with the suspicion of nosocomial infection. On the 12th day of his ICU stay, the patient was successfully extubated. He developed fever (39.5°C) and leukocytosis (18,200 per µL) on the 23rd day, and blood and urine were obtained for microbiological culture.
On day 26 of his ICU stay, the urine culture showed heavy growth of CRKP isolate (minimum inhibitory concentrations [MICs] 16 and 2 μg/ml for meropenem and colistin, respectively) that was also resistant to piperacillin/tazobactam, ceftazidime, cefepime, amikacin, gentamicin, ciprofloxacin, and levofloxacin. After acquiring susceptibility results, the combination antibiotic therapy was adjusted to colistin (9 million IU) divided into two daily doses and meropenem (1 g IV every 8 h). The patient was continued on meropenem and colistin for seven days. The patient was discharged from the hospital on day 33.
Case 2
On May 16, 2021, a 39-year-old woman with a history of multiple sclerosis (MS) and psychiatric illness presented to the emergency department with complaints of progressive decrease in consciousness, weakness, arthralgia, abdominal distension, and tenderness in the right lower quadrant and left lower quadrant.
The patient underwent surgery for necrosis and gangrene of the small bowel, specifically a resection and ileostomy on May 16th. Due to positive findings on High-Resolution Computed Tomography, there was suspicion of COVID-19 pneumonia (Covid PCR negative). Pathological findings were also observed on brain CT, and the patient received treatment with remdesivir and methylprednisolone.
During the hospitalization, the patient was empirically treated with a full course of piperacillin/tazobactam (3.375 g IV every 6 h), metronidazole (400 mg IV every 8 h), vancomycin (1 g every 12 h), and levofloxacin (750 mg IV every 24 h) for 14 days. Additionally, the patient underwent laparotomy, segmental bowel resection, and fascial repair using tension sutures and electrolysis. The patient underwent extubation twice but was reintubated due to respiratory distress and tachypnea, receiving care from the pulmonary service. On day 21 of her ICU stay, due to increased lung secretions, leukocytosis (24,800 per µL) and fever (39°C), a tracheal culture (TC) sample was sent from the patient. The culture result showed growth of CRKP isolate (minimum inhibitory concentrations [MICs] ≥ 32, and < 1 μg/ml for meropenem and colistin, respectively) that was also resistant to all tested antibiotics. According to the result of microbial culture, colistin was prescribed to the patient in two forms, injection (4.5 million IU every 12 h) and nebulizer (1 million IU every 12 h). The patient was continued on colistin for 14 days. Also, simultaneously with the administration of colistin, rifampin (10 mg/kg once daily, 10 days) was also started for the patient. Two days after the duration of treatment with colistin, a TC culture was sent from the patient, which was negative. The patient was discharged from the hospital on day 46.
Materials and Methods
Antimicrobial susceptibility testing
The antibiotic susceptibility of two K. pneumoniae isolates was determined by Kirby-Bauer disk diffusion assay according to Clinical Laboratory Standards Institute guidelines [6]. Minimum inhibitory concentration (MIC) against meropenem and colistin (Sigma Aldrich Chemicals Pvt. Ltd,India) was determined by microdilution broth method. Escherichia coli ATCC 25922 was used as quality control.
String test
String test was performed on the blood culture to identify the hypermucoviscous phenotype, and a positive result was defined by the formation of viscous strings > 5 mm in length [7].
Molecular detection of carbapenemase and ESBL-encoding genes
The presence of ESBLs genes (blaCTX-M, blaTEM, blaSHV) and carbapenemases (blaKPC, blaVIM, blaIMP, blaNDM and blaOXA-48) genes were investigated by polymerase chain reaction (PCR) as previously described [5].
Determination of capsular serotypes, virulence Genes
The genotypes of capsular serotype in K1, K2, K5, K20, K54, and K57 and virulence-associated genes, including iucA, peg-344, iutA, iroB, magA, rmpA and alls. were determined using PCR [8, 9].
Multilocus sequence typing
A multilocus sequence typing (MLST) analysis of the isolated strains was performed with PCR amplification, as previously described. House-keeping genes, including gapA, infB, mdh, pgi, phoE, rpoB, and tonB, were sequenced and compared with the MLST allele profiles available at http://www.pasteur.fr/mlst.
Results
In this study, both patients were admitted to a shared ICU in a university hospital. As shown in Table 1, both isolates were remarkably resistant to almost all tested antimicrobial agents. The MIC results showed that the NO1 isolate was intermediate to colistin and the NO2 isolate was susceptible. Also, both isolates were reported to be susceptible to tigecycline. Analysis of resistance determinants revealed that NO1 isolate carried the blaNDM, blaOXA-48-like, blaCTX-M, blaTEM, blaSHV while NO2 isolate was positive for blaNDM, blaOXA-48-like, blaSHV.
MLST analysis showed that NO1 and NO2 strains belonged to ST16 and ST337, respectively. Only, ST337 isolate demonstrated hypermucoviscosity by string length > 5 mm in the string test. The serotype of the capsule was K2. This strain was positive for virulence genes iucA, rmpA2 and rmpA. ST16 strain was negative for virulence and capsular serotype genes.
Discussion
CRKP is one of the most common carbapenem-resistant Gram-negative pathogens associated with clinical infections such as ventilator-associated pneumonia (VAP), urinary tract infection (UTI) and wound infection in the healthcare setting [10]. Colistin is one of the last resort antimicrobial agents for the treatment of infections caused by these pathogens. However, worldwide rates of colistin resistance varied between 2.8 and 10.5% for K. pneumonia over the last decade [11]. In Iran, because the only choice for treating patients infected with these strains in most hospitals is colistin there is a concern that the rate of resistance to this antibiotic will increase very quickly. In recent years, there has been an increase in Enterobacterales that co-produce two or more types of carbapenemases, and this poses a much greater public health risk. Previous studies in Iran showed that this type of isolate with two carbapenemases is frequent, especially among CRKP isolates [5, 12]. The increase in the prevalence of carbapenemase-producing isolates may lead to the need to use more colistin in our country.
In previous studies the spread of CRKP ST16 co-harboring both blaNDM-1 and blaOXA-48 has been reported, calling for careful monitoring of these highly resistant clones [13, 14]. Consistent with our research, ST16 K. pneumoniae often carried ESBL and carbapenemase genes such as blaCTX-M, blaNDM, and blaOXA-48. Similar to a previous report in Thailand [13], hypervirulence genes (iucA, peg-344, iutA, iroB, magA, rmpA and alls) were not identified in the ST16 isolate in the current study. This strain was phenotypically intermediate to colistin with a MIC value of 2 µg/ml, according to the CLSI recommendations. Since the physician had no choice but to use colistin, a combination treatment experimentally of meropenem (without determining the MIC) with colistin was started for the patient's UTI.
Among two CRKP isolates, only the isolate that recovered from the TC sample of case 2 was positive for virulence-determinant genes iucA, rmpA2 and rmpA and capsular genes of K2 corresponding to invasive K. pneumoniae ST337 clone producing blaNDM and blaOXA-48like.
The outbreak of blaNDM-5-carrying ST337 CRKP was identified from neonates in previous studies [15, 16], however, no report has described NDM-1 and OXA-48-producing CRKP ST337 clone. This is the first identification of harbouring blaNDM and blaOXA-48-like CRKP strain belonging to hypervirulent ST337. This highlights that CRKP isolates with blaNDM and blaOXA-48-like genes continue to be a problem in Iran, especially in VAP in ICUs. In this study, case 2 was intubated twice which can cause lung infection. According to a previous study, reintubation is associated with increases in the likelihood of VAP [17].
In this study, the first patient was treated with the combination of colistin plus meropenem, while the second patient was treated with the combination of colistin plus rifampin. Previous studies have shown that colistin combination therapy with other antibiotics has the potential as a treatment option for infection with CRKP. Therefore, colistin-meropenem combination may be an appropriate option if the MIC is ≤ 32 mg/L [18, 19]. According to previous reports in Iran, there is a possibility that NDM-1 and OXA-48-producing CRKP ST337 clone may be a new clone in our country. While ST16 has been previously reported in Iran and seems to be an endemic strain in Iran, it should be noted that our previous study showed that clone ST16 is a high-risk endemic clone in our hospital [12].
Considering the prevalence of carbapenemases in both isolates it is expected that both strains were resistant to the β-lactam/β-lactamase inhibitor combinations. However, cefiderocol could be an alternative to colistin, but a limitation of our study is not having tested these antibiotics.
This study has some limitations. First, due to the limited capacity of the laboratory and lack of budget, we could not use techniques such as whole-genome sequencing for further genomic investigations. Second, due to the lack of innovative β-lactam/β-lactamase inhibitor combinations discs in Iran, we could not check the antibiotic resistance profile of these drugs for CRKP isolates.
In conclusion, to the best of our knowledge, this case is the first report of K2-ST337 hvKP coproducing blaNDM and blaOXA-48-like isolate causing VAP. Due to the high prevalence of CRKP strains in Iran, some of which are hypervirulent, colistin is currently being prescribed a lot in our country. Increasing the use of colistin for multidrug-resistant Gram-negative bacterial infections will lead to the emergence of colistin resistance. Therefore, infection control programs including hand hygiene, outbreak management, environmental hygiene, surveillance, education, isolation, infection prevention policies and management should be important to prevent and control the spread of these bacteria in hospitals.
Availability of data and materials
All data are available within the manuscript.
Abbreviations
- CRKP:
-
Carbapenem-resistant Klebsiella pneumonia
- UTI:
-
Urinary tract infection
- VAP:
-
Ventilator-associated pneumonia
- cKP:
-
Classic K. pneumonia
- hvKPs:
-
Hypervirulent K. pneumonia
- ESBL:
-
Extended-spectrum β-lactamase
- ICU:
-
Intensive care unit
- MICs:
-
Minimum inhibitory concentrations
- TC:
-
Tracheal culture
- PCR:
-
Polymerase chain reaction
- MLST:
-
Multilocus sequence typing
References
Mendes G, Ramalho JF, Duarte A, Pedrosa A, Silva AC, Méndez L, et al. First outbreak of NDM-1-Producing Klebsiella pneumoniae ST11 in a Portuguese hospital centre during the COVID-19 pandemic. Microorganisms. 2022;10:1–14.
Lee CR, Lee JH, Park KS, Jeon JH, Kim YB, Cha CJ, et al. Antimicrobial resistance of hypervirulent Klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms. Front Cell Infect Microbiol. 2017;7:483.
Shen P, Berglund B, Chen Y, Zhou Y, Xiao T, Xiao Y, et al. Hypervirulence markers among non-ST11 strains of Carbapenem- and multidrug-resistant Klebsiella pneumoniae isolated from patients with bloodstream infections. Front Microbiol. 2020;11:1–8.
Talebzadeh H, Melali H, Solgi H. Association of fluoroquinolone resistance and ESBL production in hypervirulent Klebsiella pneumoniae ST11 and ST893 in Iran. Acta Microbiol Immunol Hung. 2022. https://doi.org/10.1556/030.2022.01638:135-43.
Sanikhani R, Moeinirad M, Solgi H, Hadadi A, Shahcheraghi F, Badmasti F. The face of hypervirulent Klebsiella pneumoniae isolated from clinical samples of two Iranian teaching hospitals. Ann Clin Microbiol Antimicrob. 2021;20:58.
CLSI. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 33rd ed. CLSI supplement M100 (CLSI order # Ord-836071. Downloaded on 2/6/2023). 2023.
Shon AS, Bajwa RPS, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4:107–18.
Pan YJ, Fang HC, Yang HC, Lin TL, Hsieh PF, Tsai FC, et al. Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J Clin Microbiol. 2008;56:2231–40.
Turton JF, Perry C, Elgohari S, Hampton CV. PCR characterization and typing of Klebsiella pneumoniae using capsular type-specific, variable number tandem repeat and virulence gene targets. J Med Microbiol. 2010;59:541–7.
Liao CH, Huang YT, Hsueh PR. Multicenter surveillance of capsular serotypes, virulence genes, and antimicrobial susceptibilities of Klebsiella pneumoniae causing Bacteremia in Taiwan, 2017–2019. Front Microbiol. 2022;13:1–8.
Sharma J, Sharma D, Singh A, Sunita K. Colistin resistance and management of drug resistant infections. Can J Infect Dis Med Microbiol. 2022;2022:4315030. https://doi.org/10.1155/2022/4315030.
Sanikhani R, Akbari M, Hosseinzadeh M, Siavash M, Badmasti F, Solgi H. Outbreak of colistin and carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-48 isolates in an Iranian hospital. BMC Microbiol. 2024;17(24):59.
Abe R, Akeda Y, Takeuchi D, Sakamoto N, Sugawara Y, Yamamoto N, et al. Clonal dissemination of carbapenem-resistant Klebsiella pneumoniae ST16 co-producing NDM-1 and OXA-232 in Thailand. JAC Antimicrob Resist. 2022;16:dlac084.
de Sales RO, Leaden L, Migliorini LB. A comprehensive genomic analysis of the emergent Klebsiella pneumoniae ST16 lineage: virulence, antimicrobial resistance and a comparison with the clinically relevant ST11 strain. Pathogens. 2022;11:1–19.
Bai J, Liu Y, Kang J, Song Y, Yin D, Wang S, et al. Antibiotic resistance and virulence characteristics of four carbapenem-resistant Klebsiella pneumoniae strains coharbouring blaKPC and blaNDM based on whole genome sequences from a tertiary general teaching hospital in central China between 2019 and 2021. Microb Pathog. 2023;175:1–9.
Kong Z, Cai R, Cheng C, Zhang C, Kang H, Ma P, et al. First reported nosocomial outbreak of NDM-5-producing Klebsiella pneumoniae in A neonatal unit in China. Infect Drug Resist. 2019;12:3557–66.
Li W, Zhang Y, Wang Z, Jia D, Zhang C, Ma X, et al. The risk factors of reintubation in intensive care unit patients on mechanical ventilation: a systematic review and meta-analysis. Intensive Crit Care Nurs. 2023;74:103340.
Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, et al. Synergistic activity of colistin plus Rifampin against Colistin-Resistant KPC-Producing Klebsiella pneumonia. Antimicrob Agents Chemother. 2013;57:3990–3.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Dishon Benattar Y, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391–400.
Acknowledgements
None.
Funding
This study was funded by the Isfahan University of Medical Sciences (No. 58143).
Author information
Authors and Affiliations
Contributions
Conceptualization: HS, methodology; HS, SS and AB; writing original draft preparation: HS, SS and AB; writing-review and editing: HS, SS and AB; supervision: HS. project administration: HS. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent was obtained from the patients for publication of this case report.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sokhanvari, S., Bagheri, A., Badmasti, F. et al. Molecular characterization of NDM and OXA-48-like-producing Klebsiella pneumoniae ST16 and hypervirulent ST337 clone among two patients; a case report. BMC Infect Dis 24, 850 (2024). https://doi.org/10.1186/s12879-024-09762-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12879-024-09762-7